cln-978
cln-978: developed by 1 company · 2 clinical trials tracked.
cln-978 evidence translation
What we can confirm
2 tracked trials
What it means
Source-backed records connect cln-978 to CGEM; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could cln-978 → CGEM affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Sjögren; SLESjogren's Syndrome
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cullinan Therapeutics, Inc. (CGEM) Sjögren; SLE | Phase 1/Phase 2 |
Clinical Trials (2)
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren's Disease
Primary endpoint: Safety and Tolerability
Interventionalopen36 targetStarted 2025-10Completion 2029-0314 sites · France, Germany, Italy, United StatesCullinan Therapeutics Inc.
A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Primary endpoint: Safety and tolerability
Interventionalopen24 targetStarted 2025-01Completion 2027-1220 sites · Australia, Bulgaria, France, Georgia…Cullinan Therapeutics Inc.
Frequently asked questions
Who is developing cln-978?
cln-978 is being developed by Cullinan Therapeutics, Inc..
How many clinical trials involve cln-978?
BioSniper tracks 2 clinical trials involving cln-978.